LYRA Lyra Therapeutics Inc.

FDA Catalyst Company
5.98
+0.25  (+4%)
Previous Close 5.73
Open 5.86
52 Week Low 3.3
52 Week High 9.98
Market Cap $190,250,179
Shares 31,825,055
Float 18,238,850
Enterprise Value $149,798,565
Volume 22,904
Av. Daily Volume 285,380
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Latest News

  1. In April 2022, secured $100.5 million in gross proceeds in an at-the-market, private placement of common stock that is expected to support two pivotal data readouts; cash runway extended until mid-2024

    Pivotal ENLIGHTEN Phase 3 clinical program and BEACON Phase 2 clinical trial targeting a broad spectrum of CRS patients actively recruiting patients

    WATERTOWN, Mass., May 10, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (NASDAQ:LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today reported financial results for the first quarter ended March 31, 2022, and highlighted recent…

    View Full Article
  2. LYR-210 provided up to 24 weeks of clinically meaningful global symptom improvement in CRS patients

    LYR-210 achieved significant improvement in each CRS symptom subdomain of the SNOT-22 compared to control

    LYR-210 may improve mental and physical health and quality of life of CRS patients

    WATERTOWN, Mass., April 29, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (NASDAQ:LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today is presenting additional, new data from its LANTERN Phase 2 study of LYR-210 in adult patients with chronic rhinosinusitis (CRS) at the 2022 Combined Otolaryngology…

    View Full Article
  3. WATERTOWN, Mass., April 25, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (NASDAQ:LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose, and throat (ENT) passages and other diseased tissues, today announced that the first patient was treated in the Part 1/non-randomized portion of the Phase 2 BEACON clinical trial of LYR-220 in adult patients with chronic rhinosinusitis (CRS) who have had a prior sinus surgery. LYR-220 is specifically designed to deliver six months of continuous anti-inflammatory medication in a controlled and consistent fashion to the sinonasal passages for the millions of CRS patients that continue to require treatment…

    View Full Article
  4. LYR-210 Data on Impact of Long-Acting Implantable Corticosteroid Matrices in Patients with CRS Selected as a Top Clinical Abstract

    Both Presentations Demonstrate Potential Benefit of LYR-210 to Chronic Rhinosinusitis Patients

    WATERTOWN, Mass., April 21, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (NASDAQ:LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that two new abstracts highlighting additional LANTERN study data evaluating LYR-210 in chronic rhinosinusitis (CRS) have been selected for podium presentations at the upcoming 2022 Combined Otolaryngology…

    View Full Article
View All Lyra Therapeutics Inc. News